Imprimis NJOF, LLC is recalling 1,688 units of various intraocular injection medications, including Dexamethasone Moxifloxacin, Dexamethasone Moxifloxacin Ketorolac, and Tri-Moxi+, due to the presence of glass-like particulate matter. These medications are sterile injections used during eye surgeries and were distributed nationwide across the United States. Consumers and healthcare providers are advised to stop using these products immediately and contact the manufacturer to arrange for their return.
The presence of glass-like particles in an intraocular injection can cause serious eye irritation, inflammation, or permanent tissue damage when administered during surgery. No specific injuries have been reported in this recall notice, but the contamination poses a medium risk to patient safety.
Recall #: D-0249-2026; 778 boxes of 15,540 syringes
Recall #: D-0250-2026; 596 boxes of 11,920 syringes
Recall #: D-0251-2026; 314 boxes of 6,280 syringes
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.